Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | CTSE | P14091 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PRKCG | P05129 | 1/20 | 0.34 |
| ▸ | PRKCB | P05771 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | PRKCH | P24723 | 1/20 | 0.34 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25150914 | 0.95 | USP30 (0.47) | HCAR1USP30CTSDCTSEBACE1 | |
| SCHEMBL25151026 | 0.89 | HCAR1 (0.45) | HCAR1USP30CTSDCTSEBACE1 | |
| SCHEMBL25152012 | 0.88 | USP30 (0.37) | HCAR1USP30BACE1 | |
| SCHEMBL30186853 | 0.84 | USP30 (0.49) | HCAR1USP30CTSDCTSEBACE1 | |
| SCHEMBL25150871 | 0.84 | USP30 (0.46) | HCAR1USP30CTSDCTSEBACE1 | |
| SCHEMBL25151029 | 0.82 | HCAR1 (0.51) | HCAR1USP30CTSDCTSEBACE1 | |
| SCHEMBL25151122 | 0.81 | HCAR1 (0.38) | HCAR1 | |
| SCHEMBL25151964 | 0.81 | HCAR1 (0.49) | HCAR1CTSDCTSEBACE1GPR119 | |
| SCHEMBL15206849 | 0.80 | USP30 (0.51) | HCAR1USP30CTSDCTSEBACE1 | |
| SCHEMBL30398601 | 0.80 | USP30 (0.46) | USP30GPR119THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159496-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023064880-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-4132646-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159496-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | HCAR1 4102/4885USP30 3026/4885CTSD 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.